<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697788</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-001264/1;MGH</org_study_id>
    <nct_id>NCT00697788</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients</brief_title>
  <official_title>Cardiovascular Safety of Dexmedetomidine in Pediatric Burn Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care
      units. We are studying whether this drug is cardiovascularly safe in pediatric patients who
      have recently been burned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine
      bolus/infusions in acutely burned pediatric patients. The study entails a bolus of
      dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters
      including EKG, heart rate, oxygen saturation, blood pressure, are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs (EKG, BP, O2 Sat, Heart Rate)</measure>
    <time_frame>immediately, while administering medication.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Burns</condition>
  <condition>Sedation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.</description>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric patient

          -  &gt;25% total body surface area (tbsa) burn and &lt; 90% tbsa

          -  opioid requirements &gt; 0.1 mg/kg/hour of morphine (or equivalent)

          -  midazolam requirement &gt; 0.1 mg/kg/hour

          -  treatment team determined that patient should be started on dexmedetomidine

        Exclusion Criteria:

          -  hemodynamically unstable patients (epinephrine &gt; 1.0 ug/kg/min, levophed &gt; 0.75
             ug/kg/min, dopamine &gt; 10 ug/kg/min)

          -  pregnant patients

          -  patients with history of heart block

          -  patients with congenital heart disease

          -  patients with significant hepatic dysfunction

          -  patients with urine output &lt; 0.5 ml/kg/hour [averaged] over past 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik S Shank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Burn Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 11, 2011</lastchanged_date>
  <firstreceived_date>June 12, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Erik S. Shank, MD</investigator_full_name>
    <investigator_title>Pediatric Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>burn</keyword>
  <keyword>sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
